The increasing importance of Artificial Intelligence, algorithms and Big Data in healthcare and life sciences has been a dominating feature in both law and policy discussions of late. Clinical AI tools have shown promise in predicting health trajectories of patients, recommending treatments, guiding surgical care, monitoring patients, and supporting population health management (i.e., efforts to improve the health outcomes of a community). Other types of AI, such as administrative AI tools have shown promise in reducing provider burden and increasing efficiency by recording digital notes, optimizing operational processes. These tools are at varying stages of maturity and adoption, but have already generated a considerable law and policy interest, leading to many novel regulatory proposals in EU, UK and US to name some jurisdictions. Issues such as liability, risk and biases have been in the forefront of the proposed regulations, while less attention has been focused on the impact of the proposed regulations for the innovation in this area. Gathering a panel of leading global experts on the matter of AI and Life Sciences the webinar has the ambition to explore various stakeholder perspectives related to challenges and promises of emerging AI technologies. This is part of an ongoing webinar series in collaboration between International Federation of Pharma Manufacturers Associations (IFPMA) and University of Copenhagen, Faculty of Law, and administered by Center for Advanced Studies in Biomedical Innovation Law (CeBIL).